ELTX Elicio: Net earnings per share for the last 12 months

Elicio (ELTX) - corporate logo

The future of Elicio Therapeutics (ELTX) relies on the success of new antitumor drugs and the protection of intellectual property rights. The business is currently in a state of financial deficit, spending capital on research without regular income. The strategy is based on expanding the application of Amphiphile vaccines to capture market share. This price chart reflects the EPS (TTM) dynamics, which currently stands at 46.80.

ELTX - elicio.com Net earnings per share (EPS TTM) over the range 11/23/2025 - 11/18/2026

ELTX (Elicio Therapeutics, Inc.): analytical breakdowns and indicator data

Initial company analysis:ELTX, Elicio Therapeutics, Inc.
Core merchandise of elicio.com

This indicator measures the dynamics of net income per share, reflecting the rate of change in business profitability. By analyzing the EPS YoY TTM growth efficiency metric, an investor assesses the issuer's ability to generate profit relative to the previous year. The calculation is based on a comparison of a rolling 12-month window, which eliminates seasonal distortions. For the biotech company Elicio Therapeutics (ELTX), this metric is critical during the transition from R&D expenditures to the commercialization of the AMP platform.